After a recent National Pharmaceutical Pricing Authority (NPPA) revision prices of 56 drugs that treat high blood pressure, cancer, bacterial infection and diabetes are to come down. The medicines belong to several pharmaceutical companies such as Sun Pharmaceutical Industries, Novartis, Alembic, Biocon, Lupin, Cipla, Alkem Laboratories so on. NPPA periodically revises prices of medicines which is done using the average of all drugs being sold in a particular segment.
All of these 56 drugs are Schedule – I drugs and their ceiling prices have been revised based on the Drugs (Price Control) Amendment Order of 2016. If the companies fail to comply with the revision, they will have to pay government the extra amount charged with interest. The DPCO was established to replace the 1995 act that covered only 74 drugs and did not consider most of the drugs being sold in the market.